vs
Apellis Pharmaceuticals, Inc.（APLS）与CareTrust REIT, Inc.（CTRE）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是CareTrust REIT, Inc.的1.5倍（$199.9M vs $134.9M），CareTrust REIT, Inc.净利率更高（82.5% vs -29.5%，领先112.0%），CareTrust REIT, Inc.同比增速更快（55.1% vs -5.9%），过去两年CareTrust REIT, Inc.的营收复合增速更高（46.2% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
本公司是一家英国房地产投资企业，专注于医疗类不动产投资，持有规模庞大的养老护理院资产组合。公司采用房地产投资信托（REIT）架构，在伦敦证券交易所上市，是富时250指数成分股。
APLS vs CTRE — 直观对比
营收规模更大
APLS
是对方的1.5倍
$134.9M
营收增速更快
CTRE
高出61.0%
-5.9%
净利率更高
CTRE
高出112.0%
-29.5%
两年增速更快
CTRE
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $134.9M |
| 净利润 | $-59.0M | $111.3M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 82.5% |
| 营收同比 | -5.9% | 55.1% |
| 净利润同比 | -62.2% | 113.5% |
| 每股收益（稀释后） | $-0.40 | $0.52 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSCTRE
| Q4 25 | $199.9M | $134.9M | ||
| Q3 25 | $458.6M | $132.4M | ||
| Q2 25 | $178.5M | $112.5M | ||
| Q1 25 | $166.8M | $96.6M | ||
| Q4 24 | $212.5M | $86.9M | ||
| Q3 24 | $196.8M | $77.4M | ||
| Q2 24 | $199.7M | $68.9M | ||
| Q1 24 | $172.3M | $63.1M |
净利润APLSCTRE
| Q4 25 | $-59.0M | $111.3M | ||
| Q3 25 | $215.7M | $74.9M | ||
| Q2 25 | $-42.2M | $68.5M | ||
| Q1 25 | $-92.2M | $65.8M | ||
| Q4 24 | $-36.4M | $52.1M | ||
| Q3 24 | $-57.4M | $33.4M | ||
| Q2 24 | $-37.7M | $10.8M | ||
| Q1 24 | $-66.4M | $28.7M |
营业利润率APLSCTRE
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | 58.1% | ||
| Q2 25 | -18.6% | 61.3% | ||
| Q1 25 | -50.0% | — | ||
| Q4 24 | -12.3% | — | ||
| Q3 24 | -24.0% | 43.0% | ||
| Q2 24 | -14.7% | 15.1% | ||
| Q1 24 | -36.0% | — |
净利率APLSCTRE
| Q4 25 | -29.5% | 82.5% | ||
| Q3 25 | 47.0% | 56.6% | ||
| Q2 25 | -23.6% | 60.9% | ||
| Q1 25 | -55.3% | 68.1% | ||
| Q4 24 | -17.1% | 60.0% | ||
| Q3 24 | -29.2% | 43.2% | ||
| Q2 24 | -18.9% | 15.6% | ||
| Q1 24 | -38.5% | 45.6% |
每股收益（稀释后）APLSCTRE
| Q4 25 | $-0.40 | $0.52 | ||
| Q3 25 | $1.67 | $0.35 | ||
| Q2 25 | $-0.33 | $0.35 | ||
| Q1 25 | $-0.74 | $0.35 | ||
| Q4 24 | $-0.30 | $0.30 | ||
| Q3 24 | $-0.46 | $0.21 | ||
| Q2 24 | $-0.30 | $0.07 | ||
| Q1 24 | $-0.54 | $0.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $198.0M |
| 总债务越低越好 | — | $894.2M |
| 股东权益账面价值 | $370.1M | $4.0B |
| 总资产 | $1.1B | $5.1B |
| 负债/权益比越低杠杆越低 | — | 0.22× |
8季度趋势，按日历期对齐
现金及短期投资APLSCTRE
| Q4 25 | $466.2M | $198.0M | ||
| Q3 25 | $479.2M | $712.5M | ||
| Q2 25 | $370.0M | $306.1M | ||
| Q1 25 | $358.4M | $26.5M | ||
| Q4 24 | $411.3M | $213.8M | ||
| Q3 24 | $396.9M | $377.1M | ||
| Q2 24 | $360.1M | $495.1M | ||
| Q1 24 | $325.9M | $451.2M |
总债务APLSCTRE
| Q4 25 | — | $894.2M | ||
| Q3 25 | — | $893.8M | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $822.1M | ||
| Q4 24 | — | $396.9M | ||
| Q3 24 | — | $396.7M | ||
| Q2 24 | — | $671.1M | ||
| Q1 24 | $93.1M | $595.9M |
股东权益APLSCTRE
| Q4 25 | $370.1M | $4.0B | ||
| Q3 25 | $401.2M | $4.0B | ||
| Q2 25 | $156.3M | $3.3B | ||
| Q1 25 | $164.2M | $2.9B | ||
| Q4 24 | $228.5M | $2.9B | ||
| Q3 24 | $237.1M | $2.4B | ||
| Q2 24 | $264.3M | $1.9B | ||
| Q1 24 | $266.7M | $1.7B |
总资产APLSCTRE
| Q4 25 | $1.1B | $5.1B | ||
| Q3 25 | $1.1B | $5.1B | ||
| Q2 25 | $821.4M | $4.7B | ||
| Q1 25 | $807.3M | $3.9B | ||
| Q4 24 | $885.1M | $3.4B | ||
| Q3 24 | $901.9M | $2.9B | ||
| Q2 24 | $904.5M | $2.7B | ||
| Q1 24 | $831.9M | $2.3B |
负债/权益比APLSCTRE
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.22× | ||
| Q2 25 | — | 0.35× | ||
| Q1 25 | — | 0.28× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.35× | ||
| Q1 24 | 0.35× | 0.36× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $394.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | 3.54× |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSCTRE
| Q4 25 | $-14.2M | $394.0M | ||
| Q3 25 | $108.5M | $100.9M | ||
| Q2 25 | $4.4M | $100.8M | ||
| Q1 25 | $-53.4M | $71.4M | ||
| Q4 24 | $19.4M | $244.3M | ||
| Q3 24 | $34.1M | $67.2M | ||
| Q2 24 | $-8.3M | $53.0M | ||
| Q1 24 | $-133.0M | $48.8M |
自由现金流APLSCTRE
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | — |
自由现金流率APLSCTRE
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | — |
资本支出强度APLSCTRE
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
现金转化率APLSCTRE
| Q4 25 | — | 3.54× | ||
| Q3 25 | 0.50× | 1.35× | ||
| Q2 25 | — | 1.47× | ||
| Q1 25 | — | 1.08× | ||
| Q4 24 | — | 4.68× | ||
| Q3 24 | — | 2.01× | ||
| Q2 24 | — | 4.92× | ||
| Q1 24 | — | 1.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CTRE
暂无分部数据
